PUBLISHER: iData Research Inc. | PRODUCT CODE: 2034962
PUBLISHER: iData Research Inc. | PRODUCT CODE: 2034962
Please contact us using the inquiry form for pricing information.
The global cardiac surgery device market was valued at $21.1 billion in 2025. It is expected to grow at a compound annual growth rate (CAGR) of 5.5%, reaching $30.8 billion by 2032.
This report covers the global market for cardiac surgery devices, including heart valves, structural heart devices, coronary artery bypass products, circulatory support devices, closure devices, preshaped guidewires, and extracorporeal membrane oxygenation (ECMO) products.
The analysis includes unit sales, average selling prices (ASPs), procedure numbers, market size, market shares, growth trends, market forecasts through 2032, and historical data back to 2022.
Market growth is supported by rising device prices, increasing adoption of transcatheter tricuspid valve repair, and continued expansion of transcatheter aortic valve implantation. However, anticoagulant requirements, ONCAB-related side effects, and alternative treatments in competing markets continue to limit stronger growth.
Market Overview
The global cardiac surgery device market includes a broad range of devices used to treat structural heart disease, valvular disease, coronary artery disease, heart failure, congenital defects, and severe cardiopulmonary conditions.
The market includes traditional surgical devices, transcatheter repair and replacement technologies, mechanical circulatory support systems, closure devices, bypass-related products, and ECMO systems. This wide product scope reflects the complexity of modern cardiac care.
Ongoing advancements in cardiac diagnostic technologies are helping expand the diagnosed patient population. Improvements in computed tomography and magnetic resonance imaging have made it easier to identify structural heart and valvular disease earlier and more accurately.
Historically, many patients with valve disorders were diagnosed only after symptoms appeared and disease had progressed. Broader use of advanced imaging and routine cardiovascular evaluations is now supporting earlier detection, increasing referrals for surgical and transcatheter interventions, and contributing to sustained demand for cardiac surgery devices globally.
Market Drivers
Rising Device Prices
Global inflation is driving price increases across much of the cardiac surgery device market. Although inflation is expected to slow over the forecast period, average device prices are still expected to increase.
This trend supports market value growth across many cardiac surgery segments, especially those involving advanced implants, transcatheter systems, and complex device platforms.
However, the impact of rising prices varies by market. In some regions and product categories, competitive pricing between companies moderates ASP growth. Even so, higher device prices remain an important contributor to overall market expansion.
Transcatheter Tricuspid Valve Repair
Transcatheter tricuspid valve repair is becoming an important growth driver within the cardiac surgery device market. Tricuspid regurgitation represents a large and historically underserved patient population, especially among elderly individuals and patients with heart failure.
Despite its clinical importance, tricuspid regurgitation has traditionally been underdiagnosed and undertreated. Increasing clinical awareness, better imaging, and improved screening practices are helping physicians identify clinically significant disease earlier.
Transcatheter tricuspid valve repair procedures avoid sternotomy and cardiopulmonary bypass, making them attractive for higher-risk patients. This aligns with the broader shift toward minimally invasive cardiovascular care and is expected to support growing adoption of transcatheter treatment options.
Transcatheter Aortic Valve Implantation
The global transcatheter aortic valve implantation market is expected to grow strongly over the forecast period. This growth is supported by the large patient population requiring treatment for aortic valve disease.
TAVI has become a major part of structural heart care because it provides a less invasive alternative to surgical aortic valve replacement for many patients. As eligibility expands and clinical experience increases, procedure volumes are expected to continue rising.
The market is also supported by improved imaging, earlier diagnosis, and broader referral pathways for patients with aortic stenosis. These factors are expected to keep TAVI one of the most important growth areas within the global cardiac surgery device market.
Market Limiters
Anticoagulants
The need for anticoagulants remains a major limiter for mechanical heart valves and other metal implants. Patients with these implants require consistent anticoagulation therapy because clots can form due to red blood cell and platelet damage.
These clots can block blood vessels and lead to serious complications or death. As a result, patients who receive mechanical heart valves require lifelong anticoagulant therapy, such as warfarin, along with regular blood testing for safety.
Anticoagulants can also create risks if the patient experiences bleeding, since they inhibit clot formation. Tissue heart valves and other biocompatible implants do not require the same level of anticoagulant use because they provide better blood flow dynamics and cause less clot formation. Until a biocompatible polymer can match the durability of mechanical valves while reducing clot formation, anticoagulant requirements will continue to limit growth.
ONCAB Negative Side Effects
On-pump coronary artery bypass procedures require use of a cardiopulmonary bypass pump. This exposes patient blood to foreign surfaces and has been linked to higher risk of bleeding and short-term neurocognitive effects.
These effects are often described as post-perfusion syndrome, or "pump head." Symptoms can include issues with attention, concentration, short-term memory, fine motor function, and the speed of mental and motor responses.
Stopping the heart during ONCAB procedures may also impair or damage heart muscle. In addition, clamping the aorta has been associated in some studies with the release of thrombogenic agents that may contribute to stroke risk. These concerns have encouraged some surgeons to move toward off-pump and minimally invasive CABG techniques.
Alternative Treatments in Competing Markets
Alternative treatments in adjacent cardiovascular markets continue to limit expansion of the cardiac surgery device market. Cardiovascular disease can often be treated with products and procedures included in interventional cardiology, including percutaneous coronary interventions.
Pharmaceutical treatment also plays an important role in cardiovascular disease management. In some cases, drug therapy may delay or reduce the need for surgical or device-based intervention.
As interventional and pharmaceutical options continue to develop, some patients may be treated outside the cardiac surgery device market. This creates competitive pressure on certain surgical segments, especially when less invasive alternatives are available.
Market Coverage and Data Scope
Markets Covered and Segmentation
The mechanical heart valve market is analyzed as part of the global cardiac surgery device market.
The annuloplasty repair device market is included within the broader valve repair segment.
This segment covers TMVr devices used in mitral valve repair procedures.
This segment covers TTVr devices used in tricuspid valve repair procedures.
This segment covers devices used to reduce embolic risk during certain cardiac interventions.
This segment covers products used to harvest vessels for bypass procedures.
This segment covers devices used to support vessel connection during bypass procedures.
This segment covers artificial heart replacement products.
This segment covers devices used to close patent foramen ovale defects.
This segment covers PDA closure devices.
This segment is indicated for TAVR procedures.
This segment is captured as an appendix.
Competitive Analysis
Abbott emerged as the leading competitor in the global cardiac surgery device market in 2025. The company maintains a broad and diversified portfolio across multiple cardiac surgery segments and competes strongly in most geographic markets.
Abbott is well positioned to expand its cardiac surgery presence. In August 2025, its Navitor(TM) transcatheter aortic valve implantation system received CE Mark approval for an expanded indication to treat a broader population with aortic stenosis. Abbott also received regulatory approval for its TriClip(R) system in Japan in July 2025, supporting its position in the transcatheter mitral and tricuspid intervention markets.
Edwards Lifesciences was the second-leading competitor in 2025. Although the company participates in five cardiac surgery segments, it maintained a leading position in most of those areas, except transcatheter mitral and tricuspid valve repair devices. In May 2025, its SAPIEN 3 TAVR platform received FDA approval for treating patients with asymptomatic severe aortic stenosis.
Medtronic was the third-leading competitor in 2025. Its position is supported by a broad portfolio spanning tissue and mechanical heart valves, annuloplasty repair systems, transcatheter heart valves, ONCAB and OPCAB devices, autotransfusion systems, and preshaped guidewires. In 2024, Medtronic launched the VitalFlow(TM) ECMO system and introduced Avalus Ultra(TM), its next-generation surgical aortic tissue valve.
Technology and Practice Trends
Earlier Diagnosis Through Advanced Imaging
CT and MRI improvements are enabling earlier and more accurate detection of structural heart and valvular disease. This is expanding the diagnosed patient population and increasing referrals for treatment.
Earlier diagnosis is expected to support procedural growth across valve repair, valve replacement, and other cardiac intervention segments.
Transcatheter Treatment Expansion
Transcatheter procedures remain one of the most important trends in cardiac surgery devices. These procedures reduce the need for open-heart surgery in selected patients and are especially important for elderly or high-risk populations.
TAVI, TMVr, and TTVr are expected to remain major growth areas through 2032.
Growth in Tricuspid Intervention
Tricuspid regurgitation is becoming a more recognized treatment area. Better screening and imaging are helping identify patients who previously may not have received intervention.
This trend supports growing demand for transcatheter tricuspid valve repair devices.
Large Structural Heart Portfolios
Leading competitors are building broader structural heart portfolios. Companies with strong valve repair, valve replacement, closure, and circulatory support platforms are well positioned to compete across multiple segments.
This supports cross-segment growth and strengthens account-level relationships with hospitals.
Minimally Invasive CABG and Off-Pump Techniques
Concerns related to ONCAB procedures have supported interest in off-pump and minimally invasive CABG approaches.
Products that reduce procedural trauma, shorten recovery, or avoid cardiopulmonary bypass may benefit from this trend.
ECMO and Mechanical Support Innovation
ECMO and ventricular assist technologies are important areas of continued innovation. These devices support patients with severe cardiopulmonary failure or advanced heart failure.
Product launches such as Medtronic's VitalFlow(TM) ECMO system reflect ongoing development in advanced cardiac support.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
1,316 pages of detailed market analysis, tables, and figures.
The Global Cardiac Surgery Device Market Report from iData Research answers these questions with device-level analysis, procedure-based modeling, ASP data, company share insights, and forecasts through 2032. Use it to evaluate demand, benchmark competitors, understand structural heart and surgical technology trends, and support commercial planning in the global cardiac surgery device market.
List of Figures
List of Charts
executive summary
Global Cardiac Surgery Device Market Overview
Competitive Analysis
Market Trends
Market Developments
Procedures Included
Markets Included
Regions Included
Key Report Updates
Version History
research methodology
Impact of global tariffs
Disease Overview
Global Cardiac surgery device Market Overview
Please contact us using the inquiry form for pricing information.